{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:21Z","timestamp":1793228241028,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s10620-020-06344-w","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T05:02:34Z","timestamp":1590123754000},"page":"1631-1638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Ustekinumab Does Not Increase Risk of Adverse Events: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-8508","authenticated-orcid":false,"given":"Vineet S.","family":"Rolston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"Popov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Bosworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hudesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa B.","family":"Malter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"6344_CR1","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1183\/09031936.00000914","volume":"44","author":"MA Judson","year":"2014","unstructured":"Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44:1296\u20131307. https:\/\/doi.org\/10.1183\/09031936.00000914.","journal-title":"Eur Respir J"},{"key":"6344_CR2","doi-asserted-by":"publisher","unstructured":"Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2\/3 clinical trial. J Dermatol. 2012;39:242\u2013252. https:\/\/doi.org\/10.1111\/j.1346-8138.2011.01347.x.","DOI":"10.1111\/j.1346-8138.2011.01347.x"},{"key":"6344_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","volume":"373","author":"A Gottlieb","year":"2009","unstructured":"Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet Lond Engl. 2009;373:633\u2013640. https:\/\/doi.org\/10.1016\/S0140-6736(09)60140-9.","journal-title":"Lancet Lond Engl"},{"key":"6344_CR4","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet Lond Engl. 2008;371:1665\u20131674. https:\/\/doi.org\/10.1016\/S0140-6736(08)60725-4.","journal-title":"Lancet Lond Engl"},{"key":"6344_CR5","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet Lond Engl. 2008;371:1675\u20131684. https:\/\/doi.org\/10.1016\/S0140-6736(08)60726-6.","journal-title":"Lancet Lond Engl"},{"key":"6344_CR6","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318\u20131328. https:\/\/doi.org\/10.1056\/NEJMoa1503824.","journal-title":"N Engl J Med"},{"key":"6344_CR7","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1\u00a0year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet Lond Engl. 2013;382:780\u2013789. https:\/\/doi.org\/10.1016\/S0140-6736(13)60594-2.","journal-title":"Lancet Lond Engl"},{"key":"6344_CR8","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","volume":"7","author":"BM Segal","year":"2008","unstructured":"Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 2008;7:796\u2013804. https:\/\/doi.org\/10.1016\/S1474-4422(08)70173-X.","journal-title":"Lancet Neurol"},{"key":"6344_CR9","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990\u2013999. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204655.","journal-title":"Ann Rheum Dis"},{"key":"6344_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/exd.13112","volume":"26","author":"S Khattri","year":"2017","unstructured":"Khattri S, Brunner PM, Garcet S, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol. 2017;26:28\u201335. https:\/\/doi.org\/10.1111\/exd.13112.","journal-title":"Exp Dermatol"},{"key":"6344_CR11","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Gasink C, Gao L-L, et al. Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease. N Engl J Med. 2012;367:1519\u20131528. https:\/\/doi.org\/10.1056\/NEJMoa1203572.","journal-title":"N Engl J Med"},{"key":"6344_CR12","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375:1946\u20131960. https:\/\/doi.org\/10.1056\/NEJMoa1602773.","journal-title":"N Engl J Med"},{"key":"6344_CR13","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","volume":"135","author":"WJ Sandborn","year":"2008","unstructured":"Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease. Gastroenterology. 2008;135:1130\u20131141. https:\/\/doi.org\/10.1053\/j.gastro.2008.07.014.","journal-title":"Gastroenterology"},{"key":"6344_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Reich K, Tsai T-F, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1\u00a0year: results from the CLEAR study. J Am Acad Dermatol. 2017;76:60\u201369.e9. https:\/\/doi.org\/10.1016\/j.jaad.2016.08.008.","journal-title":"J Am Acad Dermatol"},{"key":"6344_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","volume":"362","author":"CEM Griffiths","year":"2010","unstructured":"Griffiths CEM, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa0810652.","journal-title":"N Engl J Med"},{"key":"6344_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","volume":"140","author":"JM Gelfand","year":"2020","unstructured":"Gelfand JM, Shin DB, Alavi A, et al. A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U Trial). J Invest Dermatol. 2020;140:85\u201393.e2. https:\/\/doi.org\/10.1016\/j.jid.2019.07.679.","journal-title":"J Invest Dermatol"},{"key":"6344_CR17","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","volume":"392","author":"RF van Vollenhoven","year":"2018","unstructured":"van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet Lond Engl. 2018;392:1330\u20131339. https:\/\/doi.org\/10.1016\/S0140-6736(18)32167-6.","journal-title":"Lancet Lond Engl"},{"key":"6344_CR18","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201\u20131214. https:\/\/doi.org\/10.1056\/NEJMoa1900750.","journal-title":"N Engl J Med"},{"key":"6344_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/bjd.15493","volume":"177","author":"H Saeki","year":"2017","unstructured":"Saeki H, Kabashima K, Tokura Y, et al. Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study. Br J Dermatol. 2017;177:419\u2013427. https:\/\/doi.org\/10.1111\/bjd.15493.","journal-title":"Br J Dermatol"},{"key":"6344_CR20","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet Lond Engl. 2018;392:650\u2013661. https:\/\/doi.org\/10.1016\/S0140-6736(18)31713-6.","journal-title":"Lancet Lond Engl"},{"key":"6344_CR21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of Ustekinumab in axial spondyloarthritis. Arthritis Rheumatol Hoboken NJ. 2019;71:258\u2013270. https:\/\/doi.org\/10.1002\/art.40728.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"6344_CR22","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/annrheumdis-2016-209831","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Agarwal SK, Ilivanova E, et al. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Ann Rheum Dis. 2017;76:831\u2013839. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209831.","journal-title":"Ann Rheum Dis"},{"key":"6344_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2018.06.039","volume":"80","author":"C Paul","year":"2019","unstructured":"Paul C, Griffiths CEM, van de Kerkhof PCM, et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52\u00a0weeks of treatment: results from IXORA-S, a phase 3 study. J Am Acad Dermatol. 2019;80:70\u201379.e3. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.039.","journal-title":"J Am Acad Dermatol"},{"key":"6344_CR24","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s13555-018-0265-y","volume":"8","author":"J Bagel","year":"2018","unstructured":"Bagel J, Nia J, Hashim PW, et al. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week clarity results). Dermatol Ther. 2018;8:571\u2013579. https:\/\/doi.org\/10.1007\/s13555-018-0265-y.","journal-title":"Dermatol Ther"},{"key":"6344_CR25","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","volume":"391","author":"A Deodhar","year":"2018","unstructured":"Deodhar A, Gottlieb AB, Boehncke W-H, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Lond Engl. 2018;391:2213\u20132224. https:\/\/doi.org\/10.1016\/S0140-6736(18)30952-8.","journal-title":"Lancet Lond Engl"},{"key":"6344_CR26","unstructured":"Frucht DM, Holland SM. Defective monocyte costimulation for IFN-gamma production in familial disseminated Mycobacterium avium complex infection: abnormal IL-12 regulation. J Immunol Baltim Md 1950. 1996;157:411\u2013416."},{"key":"6344_CR27","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1111\/j.1462-5822.2011.01637.x","volume":"13","author":"I Godinez","year":"2011","unstructured":"Godinez I, Keestra AM, Spees A, B\u00e4umler AJ. The IL-23 axis in Salmonella gastroenteritis. Cell Microbiol. 2011;13:1639\u20131647. https:\/\/doi.org\/10.1111\/j.1462-5822.2011.01637.x.","journal-title":"Cell Microbiol"},{"key":"6344_CR28","doi-asserted-by":"publisher","first-page":"e37311","DOI":"10.1371\/journal.pone.0037311","volume":"7","author":"M Awoniyi","year":"2012","unstructured":"Awoniyi M, Miller SI, Wilson CB, Hajjar AM, Smith KD. Homeostatic regulation of Salmonella-induced mucosal inflammation and injury by IL-23. PLoS ONE. 2012;7:e37311. https:\/\/doi.org\/10.1371\/journal.pone.0037311.","journal-title":"PLoS ONE"},{"key":"6344_CR29","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028530","author":"J Yan","year":"2017","unstructured":"Yan J, Smyth MJ, Teng MWL. Interleukin (IL)-12 and IL-23 and their conflicting roles in cancer. Cold Spring Harb Perspect Biol. 2017;. https:\/\/doi.org\/10.1101\/cshperspect.a028530.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"6344_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex186","author":"A Schurich","year":"2017","unstructured":"Schurich A, Raine C, Morris V, Ciurtin C. The role of IL-12\/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade. Rheumatol Oxf Engl. 2017. https:\/\/doi.org\/10.1093\/rheumatology\/kex186.","journal-title":"Rheumatol Oxf Engl"},{"key":"6344_CR31","unstructured":"Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (Updated on March 2011) 2011."},{"key":"6344_CR32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.gtc.2017.05.013","volume":"46","author":"P Deepak","year":"2017","unstructured":"Deepak P, Sandborn WJ. Ustekinumab and anti-interleukin-23 agents in Crohn\u2019s disease. Gastroenterol Clin N Am. 2017;46:603\u2013626. https:\/\/doi.org\/10.1016\/j.gtc.2017.05.013.","journal-title":"Gastroenterol Clin N Am"},{"key":"6344_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/14712598.2020.1707800","volume":"20","author":"FS Macaluso","year":"2020","unstructured":"Macaluso FS, Maida M, Ventimiglia M, Cottone M, Orlando A. Effectiveness and safety of Ustekinumab for the treatment of Crohn\u2019s disease in real-life experiences: a meta-analysis of observational studies. Expert Opin Biol Ther. 2020;20:193\u2013203. https:\/\/doi.org\/10.1080\/14712598.2020.1707800.","journal-title":"Expert Opin Biol Ther"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06344-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-020-06344-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06344-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T23:42:27Z","timestamp":1621640547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-020-06344-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["6344"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06344-w","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]},"assertion":[{"value":"7 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"David Hudesman was the consultant for Pfizer, Takeda, Janssen Biotech, Abbvie, and Salix. Research support was from Pfizer. Shannon Chang was the consultant for Takeda, Pfizer, and Oshi Health. Lisa Malter was the consultant for Takeda, Pfizer, Abbvie, Prometheus, Janssen, Merck, UCB, and Gilead. The remaining authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}